Cargando…

Evaluation of the Safety and Effectiveness of Add-On Tacrolimus in Patients with Rheumatoid Arthritis Who Failed to Show an Adequate Response to Biological DMARDs: The Interim Results of a Specific Drug Use-Results Survey of Tacrolimus

BACKGROUND: Tacrolimus (TAC) is an immunosuppressive macrolide that blocks T-cell activation by specifically inhibiting calcineurin. TAC was approved in Japan for the treatment of rheumatoid arthritis (RA) in 2005. However, the safety and effectiveness of TAC adding on to biological disease-modifyin...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishida, Kota, Shiraki, Katsuhisa, Yoshiyasu, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662943/
https://www.ncbi.nlm.nih.gov/pubmed/26386566
http://dx.doi.org/10.1007/s40268-015-0106-8
_version_ 1782403222595436544
author Ishida, Kota
Shiraki, Katsuhisa
Yoshiyasu, Takashi
author_facet Ishida, Kota
Shiraki, Katsuhisa
Yoshiyasu, Takashi
author_sort Ishida, Kota
collection PubMed
description BACKGROUND: Tacrolimus (TAC) is an immunosuppressive macrolide that blocks T-cell activation by specifically inhibiting calcineurin. TAC was approved in Japan for the treatment of rheumatoid arthritis (RA) in 2005. However, the safety and effectiveness of TAC adding on to biological disease-modifying anti-rheumatic drugs (DMARDs) in the real clinical setting may not be clear enough. OBJECTIVES: We report here the interim results of post marketing surveillance (PMS) of TAC adding on to biological DMARDs in RA patients who failed to show an adequate response to biological DMARDs. METHODS: Patients who had an inadequate response to biological DMARDs were enrolled. An inadequate response to biological DMARDs was defined as that all of the following conditions were met: a Simplified Disease Activity Index (SDAI) score of >3.3 when TAC was started; both the tender joint count and swollen joint count were the same or increased compared with those at 4–8 weeks prior to TAC; and biological DMARDs were used for at least 8 weeks prior to TAC. This study was conducted in compliance with the ministerial ordinance on “Good Post-Marketing Study Practice” (GPSP). RESULTS: The safety data collection and evaluation for 172 patients and effectiveness data collection and evaluation for 165 patients were reported. The mean age was 61.9 years. Adverse drug reactions occurred in 18 patients. The mean SDAI decreased from 20.1 at baseline to 11.7 at week 24. CONCLUSIONS: TAC is well tolerated and effective when added on to biological DMARDs in RA patients who failed to achieve an adequate response to biological DMARDs.
format Online
Article
Text
id pubmed-4662943
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-46629432015-12-04 Evaluation of the Safety and Effectiveness of Add-On Tacrolimus in Patients with Rheumatoid Arthritis Who Failed to Show an Adequate Response to Biological DMARDs: The Interim Results of a Specific Drug Use-Results Survey of Tacrolimus Ishida, Kota Shiraki, Katsuhisa Yoshiyasu, Takashi Drugs R D Original Research Article BACKGROUND: Tacrolimus (TAC) is an immunosuppressive macrolide that blocks T-cell activation by specifically inhibiting calcineurin. TAC was approved in Japan for the treatment of rheumatoid arthritis (RA) in 2005. However, the safety and effectiveness of TAC adding on to biological disease-modifying anti-rheumatic drugs (DMARDs) in the real clinical setting may not be clear enough. OBJECTIVES: We report here the interim results of post marketing surveillance (PMS) of TAC adding on to biological DMARDs in RA patients who failed to show an adequate response to biological DMARDs. METHODS: Patients who had an inadequate response to biological DMARDs were enrolled. An inadequate response to biological DMARDs was defined as that all of the following conditions were met: a Simplified Disease Activity Index (SDAI) score of >3.3 when TAC was started; both the tender joint count and swollen joint count were the same or increased compared with those at 4–8 weeks prior to TAC; and biological DMARDs were used for at least 8 weeks prior to TAC. This study was conducted in compliance with the ministerial ordinance on “Good Post-Marketing Study Practice” (GPSP). RESULTS: The safety data collection and evaluation for 172 patients and effectiveness data collection and evaluation for 165 patients were reported. The mean age was 61.9 years. Adverse drug reactions occurred in 18 patients. The mean SDAI decreased from 20.1 at baseline to 11.7 at week 24. CONCLUSIONS: TAC is well tolerated and effective when added on to biological DMARDs in RA patients who failed to achieve an adequate response to biological DMARDs. Springer International Publishing 2015-09-19 2015-12 /pmc/articles/PMC4662943/ /pubmed/26386566 http://dx.doi.org/10.1007/s40268-015-0106-8 Text en © The Author(s) 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research Article
Ishida, Kota
Shiraki, Katsuhisa
Yoshiyasu, Takashi
Evaluation of the Safety and Effectiveness of Add-On Tacrolimus in Patients with Rheumatoid Arthritis Who Failed to Show an Adequate Response to Biological DMARDs: The Interim Results of a Specific Drug Use-Results Survey of Tacrolimus
title Evaluation of the Safety and Effectiveness of Add-On Tacrolimus in Patients with Rheumatoid Arthritis Who Failed to Show an Adequate Response to Biological DMARDs: The Interim Results of a Specific Drug Use-Results Survey of Tacrolimus
title_full Evaluation of the Safety and Effectiveness of Add-On Tacrolimus in Patients with Rheumatoid Arthritis Who Failed to Show an Adequate Response to Biological DMARDs: The Interim Results of a Specific Drug Use-Results Survey of Tacrolimus
title_fullStr Evaluation of the Safety and Effectiveness of Add-On Tacrolimus in Patients with Rheumatoid Arthritis Who Failed to Show an Adequate Response to Biological DMARDs: The Interim Results of a Specific Drug Use-Results Survey of Tacrolimus
title_full_unstemmed Evaluation of the Safety and Effectiveness of Add-On Tacrolimus in Patients with Rheumatoid Arthritis Who Failed to Show an Adequate Response to Biological DMARDs: The Interim Results of a Specific Drug Use-Results Survey of Tacrolimus
title_short Evaluation of the Safety and Effectiveness of Add-On Tacrolimus in Patients with Rheumatoid Arthritis Who Failed to Show an Adequate Response to Biological DMARDs: The Interim Results of a Specific Drug Use-Results Survey of Tacrolimus
title_sort evaluation of the safety and effectiveness of add-on tacrolimus in patients with rheumatoid arthritis who failed to show an adequate response to biological dmards: the interim results of a specific drug use-results survey of tacrolimus
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662943/
https://www.ncbi.nlm.nih.gov/pubmed/26386566
http://dx.doi.org/10.1007/s40268-015-0106-8
work_keys_str_mv AT ishidakota evaluationofthesafetyandeffectivenessofaddontacrolimusinpatientswithrheumatoidarthritiswhofailedtoshowanadequateresponsetobiologicaldmardstheinterimresultsofaspecificdruguseresultssurveyoftacrolimus
AT shirakikatsuhisa evaluationofthesafetyandeffectivenessofaddontacrolimusinpatientswithrheumatoidarthritiswhofailedtoshowanadequateresponsetobiologicaldmardstheinterimresultsofaspecificdruguseresultssurveyoftacrolimus
AT yoshiyasutakashi evaluationofthesafetyandeffectivenessofaddontacrolimusinpatientswithrheumatoidarthritiswhofailedtoshowanadequateresponsetobiologicaldmardstheinterimresultsofaspecificdruguseresultssurveyoftacrolimus